Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor

Summary by The Manila Times
PALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc ('Forward”), a biotechnology company developing oral small molecule therapies for...

1 Articles

The Manila TimesThe Manila Times
Lean Right

Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor

PALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc ('Forward”), a biotechnology company developing oral small molecule therapies for...

·Manila, Philippines
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Manila Times broke the news in Manila, Philippines on Thursday, October 30, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Palm Beach Gardens icon

Palm Beach Gardens

News
For You
SearchBlindspotLocal